SJEPD031238_D1.RNA-Seq
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 19.7
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -1.871812684
- umap2_2d
- 1.51422433
- umap1_3d
- -0.03673047
- umap2_3d
- 3.82087177
- umap3_3d
- -3.342689736
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.570
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.510
- OXIDATIVE_PHOSPHORYLATION+0.480
- DNA_REPAIR+0.420
- PROTEIN_SECRETION+0.380
- UNFOLDED_PROTEIN_RESPONSE+0.320
- PANCREAS_BETA_CELLS+0.270
- MTORC1_SIGNALING+0.250
- MYC_TARGETS_V2+0.250
Top 10 suppressed
- MYOGENESIS-0.370
- KRAS_SIGNALING_DN-0.240
- APICAL_JUNCTION-0.210
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- HYPOXIA-0.190
- TNFA_SIGNALING_VIA_NFKB-0.190
- IL2_STAT5_SIGNALING-0.180
- COAGULATION-0.160
- INFLAMMATORY_RESPONSE-0.160
- IL6_JAK_STAT3_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2727-01A-01R-0980-07 | — | cohortSQ2 | 0.879 |
| 2 | BS_FTKPQ5FZ | Supratentorial Ependymoma | — | 0.866 |
| 3 | E0DE33EA-C3DF-478E-9C4D-86E3C7B3A1D9 | — | — | 0.855 |
| 4 | SRR10842371 | — | — | 0.853 |
| 5 | EE4F9349-F750-4471-BFE7-7230784569E1 | — | — | 0.850 |
| 6 | SJEPD030367_D1.RNA-Seq | EPN | Anaplastic EPN | 0.848 |
| 7 | BS_74G5K7JF | Supratentorial Ependymoma | — | 0.845 |
| 8 | BS_M84H3KXA | Med | Medulloblastoma | 0.838 |
| 9 | MDT-AP-2030 | Med | Medulloblastoma | 0.834 |
| 10 | SRR15030853 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.420 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |